INTERVIEW: Mirum’s Chris Peetz Discusses Positive Topline Data on LIVMARLI for PFIC (Pt. 2)
Photo courtesy of Mirum

INTERVIEW: Mirum’s Chris Peetz Discusses Positive Topline Data on LIVMARLI for PFIC (Pt. 2)

Before you read on, make sure to check out Part 1 of our interview. In Part 1, Chris Peetz discusses his background, why he joined Mirum, and the process of evaluating LIVMARLI…

Continue Reading INTERVIEW: Mirum’s Chris Peetz Discusses Positive Topline Data on LIVMARLI for PFIC (Pt. 2)

Raising Awareness of Recessive Dystrophic Epidermolysis Bullosa: Patterson’s Story (Pt. 2)

Before you read on, make sure to check out Part 1 of our interview, where Annie, Peter, and Patterson discuss what recessive dystrophic epidermolysis bullosa (RDEB) is, Patterson's diagnostic journey, and how…

Continue Reading Raising Awareness of Recessive Dystrophic Epidermolysis Bullosa: Patterson’s Story (Pt. 2)
Serdexmethylphenidate for Idiopathic Hypersomnia Earns Orphan Drug Designation
https://pixabay.com/en/toddler-boy-sleeping-child-1245674/

Serdexmethylphenidate for Idiopathic Hypersomnia Earns Orphan Drug Designation

  In the United States, the FDA grants Orphan Drug designation to drugs or biologics intended to treat, diagnose, or prevent rare diseases or conditions. A rare disease is one…

Continue Reading Serdexmethylphenidate for Idiopathic Hypersomnia Earns Orphan Drug Designation
INTERVIEW: Mirum’s Chris Peetz Discusses Positive Topline Data on LIVMARLI for PFIC (Pt. 1)
Photo courtesy of Mirum

INTERVIEW: Mirum’s Chris Peetz Discusses Positive Topline Data on LIVMARLI for PFIC (Pt. 1)

The American Association for the Study of Liver Disease (AASLD) held its annual Liver Meeting from November 4-7, 2022 in Washington, D.C. During the meeting, Mirum Pharmaceuticals shared two late-breaker…

Continue Reading INTERVIEW: Mirum’s Chris Peetz Discusses Positive Topline Data on LIVMARLI for PFIC (Pt. 1)
Advocating for Cancer Biomarker Testing: How Brittany Turned her RET+ NSCLC Diagnosis into Action (Pt. 2)
Photo courtesy of Brittany

Advocating for Cancer Biomarker Testing: How Brittany Turned her RET+ NSCLC Diagnosis into Action (Pt. 2)

Before you read further, make sure to check out Part 1 of our interview, where Brittany discusses what non-small cell lung cancer (NSCLC) is, her diagnostic journey, and how she learned that…

Continue Reading Advocating for Cancer Biomarker Testing: How Brittany Turned her RET+ NSCLC Diagnosis into Action (Pt. 2)
Advocating for Cancer Biomarker Testing: How Brittany Turned her RET+ NSCLC Diagnosis into Action (Pt. 1)
Photo courtesy of Brittany

Advocating for Cancer Biomarker Testing: How Brittany Turned her RET+ NSCLC Diagnosis into Action (Pt. 1)

On the one-year anniversary of her RET+ non-small cell lung cancer (NSCLC) diagnosis, 37-year-old Brittany Hawkins had spent some time reflecting on her journey. When she was just seventeen years…

Continue Reading Advocating for Cancer Biomarker Testing: How Brittany Turned her RET+ NSCLC Diagnosis into Action (Pt. 1)